There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Henry Schein (HSIC – Research Report) and scPharmaceuticals (SCPH – Research Report) with bullish sentiments.
Henry Schein (HSIC)
In a report released today, Michael Petusky from Barrington maintained a Buy rating on Henry Schein, with a price target of $90.00. The company’s shares closed last Thursday at $74.13.
According to TipRanks.com, Petusky is a 4-star analyst with an average return of
Henry Schein has an analyst consensus of Hold, with a price target consensus of $82.00.
See today’s best-performing stocks on TipRanks >>
scPharmaceuticals (SCPH)
Maxim Group analyst Naz Rahman maintained a Buy rating on scPharmaceuticals yesterday and set a price target of $20.00. The company’s shares closed last Thursday at $7.05.
According to TipRanks.com, Rahman has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on scPharmaceuticals is a Strong Buy with an average price target of $17.75, which is a 140.8% upside from current levels. In a report issued on September 7, Craig-Hallum also initiated coverage with a Buy rating on the stock with a $20.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HSIC:
